← Back to patent-cliff list
BI 3000202
Tier C — Watch / tradeBI 3000202
Boehringer Ingelheim International Gmbh
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Systemic lupus erythematosus, Hepatic function decline, 1型干扰素病
Regional status
US
Phase II
2026-04-20
EU
Phase II
2026-04-20
China
Phase II
2026-04-20
Japan
Phase II
2026-04-20
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of BI 3000202?
Approved indications include: Systemic lupus erythematosus, Hepatic function decline, 1型干扰素病.
When does the BI 3000202 patent expire?
No public expiry year is available for BI 3000202 yet; this page updates once verified.
How do I get a quote for BI 3000202 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29